Tests a radioactive drug, AZD2284, in men with advanced prostate cancer

Trial details

Who runs it

AstraZeneca

Trial code

NCT06879041

Record updated

16 October 2026

Original description

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.Read full original descriptionShow less

A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Inclusion: eria:; • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; • Histologically confirmed diagnosis of adenocarcinoma of the prostate without strong clinical suspicion of majority neuroendocrine differentiation; • Must have had prior bilateral orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L); • At least one metastatic lesion present on baseline Computed Tomography (CT), Magnetic Resonance Imaging (MRI), or bone scan obtained ≤ 28 days prior to the first dose of Investigational Medicinal Product (IMP). Participants may have non-measurable lesions including bone only metastases; • Adequate organ function; • Part A only: Metastatic prostate cancer considered to be stable or progressing metastatic castration resistant prostate cancer (mCRPC); • Part B only: Progressing mCRPC defined as meeting at least one of following documented criteria -; a)Serum/plasma PSA progression; b)Soft-tissue progression; c)Progression of bone disease; • Part B Dose Escalation: Previously treated with at least 2 prior lines of systemic anti-cancer therapy for mCRPC. Prior lines must include:; a)At least 1 androgen receptor pathway inhibitor (ARPI); b)A poly (adp-ribose) polymerase (PARP) inhibitor for participants with known BRCA mutation; c)A checkpoint inhibitor for participants with known microsatellite instability-high (MSI-H), deficient mismatch pair (dMMR), or tumor mutational burden (TMB) ≥ 10 mut/Mb; • Part B Dose Expansion: Previously treated with at least 1 prior line of systemic anti-cancer therapy for mCRPC. Prior lines must include:; (a)At least 1 ARPI; (b)A PARP inhibitor for participants with known BRCA mutation per local practice, unless ineligible per Investigator decision; (c)A checkpoint inhibitor for participants with known MSI-H, dMMR, or TMB ≥ 10 mut/Mb; (d)No previous cytotoxic chemotherapy for CRPC. Taxanes for metastatic hormone sensitive prostate cancer (mHSPC) is acceptable if the last cycle Day 1 was > 12 months before first study treatment; (e)Previous treatment with prostate specific membrane antigen radioligand therapy (PSMA-RLT) or Radium-223 is allowed but not required. Participants who have had prior radiation therapy, including therapeutic radiopharmaceuticals, external bean radiation therapy (EBRT), and/or brachytherapy are eligible, subject to satisfying all other inclusion/exclusion criteria. Therapeutic radiopharmaceuticals will be considered a prior line of systemic therapy; Main.

Exclusion: • Treatment with any radiopharmaceutical within 6 weeks of the first dose of Investigational Medicinal Product (IMP); • Radiation therapy (RT) or external beam radiation therapy (EBRT) within 28 days prior to the first dose and all RT-related events have not recovered to Grade ≤ 1; • Administration of any systemic cytotoxic or investigational therapy ≤ 28 days of the first dose of IMP or 5 half-lives, whichever is shorter; • All prior treatment-related adverse events must have resolved to Grade ≤ 1; • Concurrent severe and/or uncontrolled illness not related to cancer and/or social situation that would limit compliance with study requirements; • Known or suspected allergies or contraindications to any of the investigational drugs or any component of the investigational drug formulation; • Chronic corticosteroid use greater than 10 mg prednisone equivalent daily; • Clinically relevant proteinuria; • Diffuse and intense osseous radiotracer uptake on bone scintigraphy or PSMA imaging characteristic of a superscan.

ClinicalTrials.gov NCT06879041